A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES AFTER PROGRESSION ON PRIOR PD-1 INHIBITOR TREATMENT

Registry ID

SGN35-033

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

SEAGEN INC.

Start date

2023-02-10

Completion date

2025-02-27

Last update

2022-04-26

Conditions

• MALIGNANCIES

Related clinical trials

• A RANDOMIZED PHASE I/II STUDY OF ONIVYDE IN COMBINATION WITH TALAZOPARIB OR TEMOZOLOMIDE IN CHILDREN AND YOUNG ADULTS WITH RECURRENT SOLID MALIGNANCIES AND EWING SARCOMA
• PRIMARY THROMBOPROPHYLAXIS IN PATIENTS WITH MALIGNANCY AND CENTRAL VENOUS CATHETERS: A RANDOMIZED CONTROLLED TRIAL (TRIM-LINE)
• A PHASE I, OPEN-LABEL, MULTI-CENTER STUDY OF SAFETY AND DOSE OF FAZ053 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES
• A PHASE IIIB/IV SAFETY TRIAL OF FLAT DOSE NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN PARTICIPANTS WITH ADVANCED MALIGNANCIES

View on source registry